Identification Generic Name (2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol DrugBank Accession Number DB07504 Background Not Available Type Small Molecule Groups Experimental Structure 
 
 
 3D Download  MOL SDF 3D-SDF PDB SMILES InChI 
 
 
  Similar Structures Structure for (2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol (DB07504) ×  Close Weight Average: 458.352  Monoisotopic: 457.111337684  Chemical Formula C 21 H 24 BrN 5 O 2 Synonyms Not Available Pharmacology Indication Not Available Reduce drug development failure rates Build, train, & validate machine-learning models with evidence-based and structured datasets. See how     Build, train, & validate predictive machine-learning models with structured datasets. See how Contraindications & Blackbox Warnings Avoid life-threatening adverse drug events Improve clinical decision support with information on  contraindications & blackbox warnings, population restrictions, harmful risks, & more. Learn more     Avoid life-threatening adverse drug events & improve clinical decision support. Learn more Pharmacodynamics Not Available Mechanism of action Target Actions Organism U Cyclin-dependent kinase 2 Not Available Humans Absorption Not Available Volume of distribution Not Available Protein binding Not Available Metabolism Not Available Route of elimination Not Available Half-life Not Available Clearance Not Available Adverse Effects Improve decision support & research outcomes With structured adverse effects data, including:  blackbox warnings, adverse reactions, warning & precautions, & incidence rates. Learn more     Improve decision support & research outcomes with our structured adverse effects data. Learn more Toxicity Not Available Pathways Not Available Pharmacogenomic Effects/ADRs  
 
 
 Not Available Interactions Drug Interactions  
 
 
 This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.  Not Available Food Interactions Not Available Categories Drug Categories Not Available Classification Not classified Affected organisms Not Available Chemical Identifiers UNII Not Available CAS number Not Available InChI Key MEIJADBULOETOV-QGZVFWFLSA-N InChI InChI=1S/C21H24BrN5O2/c1-27(2)13-17(28)14-29-18-10-8-16(9-11-18)25-21-23-12-19(22)20(26-21)24-15-6-4-3-5-7-15/h3-12,17,28H,13-14H2,1-2H3,(H2,23,24,25,26)/t17-/m1/s1 IUPAC Name (2R)-1-(4-{[5-bromo-6-(phenylimino)-1,6-dihydropyrimidin-2-yl]amino}phenoxy)-3-(dimethylamino)propan-2-ol SMILES [H]N(C1=CC=C(OC[C@H](O)CN(C)C)C=C1)C1=NC=C(Br)C(=N1)N([H])C1=CC=CC=C1 References General References Not Available External Links PubChem Compound 445957 PubChem Substance 99443975 ChemSpider 393437 ZINC ZINC000000589075 PDBe Ligand BYP PDB Entries 1h08 Clinical Trials Clinical Trials  
 
 
 Phase Status Purpose Conditions Count Pharmacoeconomics Manufacturers Not Available Packagers Not Available Dosage Forms Not Available Prices Not Available Patents Not Available Properties State Solid Experimental Properties Not Available Predicted Properties Property Value Source Water Solubility 0.035 mg/mL ALOGPS logP 3.83 ALOGPS logP 3.23 Chemaxon logS -4.1 ALOGPS pKa (Strongest Acidic) 9.13 Chemaxon pKa (Strongest Basic) 8.65 Chemaxon Physiological Charge 2 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 81.48 Å 2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 121.28 m 3 ·mol -1 Chemaxon Polarizability 46.32 Å 3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon Predicted ADMET Features Property Value Probability Human Intestinal Absorption + 0.9559 Blood Brain Barrier - 0.5576 Caco-2 permeable + 0.5135 P-glycoprotein substrate Substrate 0.6789 P-glycoprotein inhibitor I Non-inhibitor 0.5869 P-glycoprotein inhibitor II Inhibitor 0.9298 Renal organic cation transporter Non-inhibitor 0.7383 CYP450 2C9 substrate Non-substrate 0.8529 CYP450 2D6 substrate Non-substrate 0.7957 CYP450 3A4 substrate Substrate 0.5236 CYP450 1A2 substrate Inhibitor 0.5432 CYP450 2C9 inhibitor Non-inhibitor 0.722 CYP450 2D6 inhibitor Non-inhibitor 0.5314 CYP450 2C19 inhibitor Non-inhibitor 0.6006 CYP450 3A4 inhibitor Non-inhibitor 0.7024 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.6201 Ames test Non AMES toxic 0.636 Carcinogenicity Non-carcinogens 0.8816 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.3669 LD50, mol/kg  Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8155 hERG inhibition (predictor II) Inhibitor 0.6061    ADMET data is predicted using  admetSAR , a free tool for evaluating chemical ADMET properties. ( 23092397 )  Spectra Mass Spec (NIST) Not Available Spectra Not Available Targets Build, predict & validate machine-learning models Use our structured and evidence-based datasets to  unlock newinsights and accelerate drug research. Learn more     Use our structured and evidence-based datasets to unlock new insights and accelerate drug research. Learn more 
 
 
  Details 1.  Cyclin-dependent kinase 2 Kind Protein Organism Humans Pharmacological action Unknown General Function Metal ion binding Specific Function Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, N... Gene Name CDK2 Uniprot ID P24941 Uniprot Name Cyclin-dependent kinase 2 Molecular Weight 33929.215 Da References Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [ Article ]  × Identify potential medication risks Easily compare up to 40 drugs with our drug interaction checker. Get severity rating, description, and management advice.  Learn more      Drug created at September 15, 2010 21:23 / Updated at June 12, 2020 16:52 